Bone Biologics Corp
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
BBLG$0.33-0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current Assets | ||
| Cash | $3,325,131 | $3,026,569 |
| Advances on research and development contract services | 258,059 | 328,844 |
| Prepaid insurance | 268,179 | 372,350 |
| Prepaid expenses | 10,000 | 10,000 |
| Total current assets | $3,861,369 | $3,737,763 |
| Total assets | $3,861,369 | $3,737,763 |
| Liabilities and Stockholders’ Equity | ||
| Current Liabilities | ||
| Accounts payable and accrued expenses | $373,042 | $360,662 |
| Research and development contract liabilities | - | - |
| Accrued legal settlement | - | 414,989 |
| Warrant liability | 4,670 | 55,751 |
| Total current liabilities | 377,712 | 831,402 |
| Total liabilities | 377,712 | 831,402 |
| Commitments and Contingencies | - | - |
| Stockholders’ Equity | ||
| Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at December 31, 2024 and 2023 | - | - |
| Common stock, $0.001 par value per share; 100,000,000 shares authorized; 2,953,982 and 534,238 shares issued and outstanding at December 31, 2024 and 2023, respectively | 2,953 | 534 |
| Additional paid-in capital | 88,502,082 | 83,814,785 |
| Accumulated deficit | (85,021,378) | (80,908,958) |
| Total stockholders’ equity | 3,483,657 | 2,906,361 |
| Total liabilities and stockholders’ equity | $3,861,369 | $3,737,763 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.